T. Andrew Crockett
2022
In 2022, T. Andrew Crockett earned a total compensation of $6.5M as Chief Executive Officer at Carbylan Therapeutics, a 181% increase compared to previous year.
Compensation breakdown
| Bonus | $363,000 |
|---|---|
| Option Awards | $3,630,920 |
| Salary | $605,000 |
| Stock Awards | $1,885,275 |
| Other | $12,252 |
| Total | $6,496,447 |
Crockett received $3.6M in option awards, accounting for 56% of the total pay in 2022.
Crockett also received $363K in bonus, $605K in salary, $1.9M in stock awards and $12.3K in other compensation.
Rankings
In 2022, T. Andrew Crockett's compensation ranked 453rd out of 5,756 executives tracked by ExecPay. In other words, Crockett earned more than 92.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 453 out of 5,756 | 92nd |
Division Manufacturing | 188 out of 3,133 | 94th |
Major group Chemicals And Allied Products | 50 out of 1,419 | 97th |
Industry group Drugs | 38 out of 1,320 | 97th |
Industry Pharmaceutical Preparations | 25 out of 966 | 97th |
Source: SEC filing on August 14, 2023.
Crockett's colleagues
We found two more compensation records of executives who worked with T. Andrew Crockett at Carbylan Therapeutics in 2022.